The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
The US Food and Drug Administration has approved the use of a novel painkiller as an effective treatment for short-term ...
The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.
Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...
Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...
The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.
Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class ...
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...